Cincinnati, Ohio

Velocity Clinical Research at MidWest Eye Center, Cincinnati

Velocity's Ophthalmology research site in Cincinnati partners with MidWest Eye Center to conduct clinical trials related to disorders of the eye. This site explores medicines being studied for their effect on diabetic macular edema, macular degeneration, dry eye, diabetic retinopathy, and more. Acquired by Velocity in 2022, the Cincinnati location conducted clinical trials for years, first with Sterling Research, then as part of Meridian Clinical Research.

Through the partnership with MidWest Eye, the site is easily accessible to thousands of patients in the tri-state area, including those established with the practice. All trials are performed in accordance with ICH and FDA guidelines, and in compliance with GCP. Our Cincinnati team is committed to being a resource for study participants, to providing the highest quality of patient care with compassion and kindness, and to advancing medicine through research.

Velocity Clinical Research at MidWest Eye Center, Cincinnati
2055 Reading Rd., Suite 330, Cincinnati, OH 45202

Phone: (513) 643-3937

Email: info@velocityclinical.com

Find a Clinical Trial in Cincinnati
Sign up below to speak with an enrollment specialist about available research studies in Cincinnati.

Follow Velocity on Facebook for company updates and more.

Portrait Of Medical Team Standing Outside Hospital

About Velocity Clinical Research

140,000+ people have a joined a study at Velocity

Many people enjoy the study experience and have joined several clinical trials at Velocity.

Velocity has decades of research experience

With sites that were established as long ago as 1986, Velocity has experts who have supported clinical trials for decades.

Velocity studies are led by healthcare professionals

All clinical trials conducted at Velocity are overseen by the U.S. Food and Drug Administration (FDA).

Our experienced research team in Cincinnati

Every clinical trial is overseen by a Principal Investigator – a physician who is responsible for the rights, safety and welfare of the study participants. All physicians at Velocity are board certified in their specialty area(s) and all research staff is trained in clinical research regulations, including GCP and HIPAA. Our clinical research team in Cincinnati is dedicated to conducting quality research in a professional and caring environment.

  • Christopher Devine, MD, FACS

    Principal Investigator
    Christopher Devine, MD, FACS is a board certified Ophthamologist who specializes in vitreoretinal diseases and surgery. Dr. Devine graduated Summa Cum Laude with his Bachelors of Science degree from the University of Cincinnati and received his Doctor of Medicine degree from Northwestern University. He spent his residency at the University of Tennessee. A few of the conditions Dr. Devine treats include Floaters/Flashes, Macular Degeneration, Retinitis Pigmentosa, Macular Hole, Macular Pucker, Retinal Tear, and Diabetes.

  • Stephan Dixon, MD

    Principal Investigator

Complete the form to start your clinical trial journey in Cincinnati

Beyond helping advance medicine, you may also:

  • Get care from a local doctor at no cost
  • Learn about new medicines in development
  • Receive study-related medical exams at no cost
  • Get paid for participating (amounts differ for each study)

After you submit your info, a Velocity staff member will review your info. They will contact you to talk about the study, or others that may be right for you.

Health insurance is generally not needed to join a clinical trial.

Remember, there is never an obligation to join — we're here to help you make the best decision.

Submit your info

Sponsors and CROs

From the leading pharma companies, to the most pioneering biotech startups, Velocity supports those who are exploring new frontiers in human health. Whether you’re ready to conduct a single-site study or a complex, high-volume clinical trial, trust Velocity.

clinical research team

It all starts with people like you.

Without clinical trial participants, it would not be possible to create new medicines, treatments, and cures.